LEU011

PreclinicalBiologic

LLeucid Bio

LEU011 is one of 4 biologic programs targeting Tumor, Solid. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tumor, SolidRecruiting

Tumor, SolidPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Tumor, Solid

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Phase 1

1 2

Ulixertinib

NNational Cancer Institute (NCI)

Phase 1

1 3

XNW29016

EEvopoint Biosciences Inc.

Preclinical

1 4

LEU011

LLeucid Bio

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Tumor, Solid

NCT06193902

Clinical

Trials by Indication[1]

Tumor, Solid1 trial

A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours

Recruiting·LLeucid Bio·Preclinical·NCT06193902·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LEU011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LEU011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LEU011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leucid Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: LLeucid Bio

LEU011

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Tumor, Solid1 trial

References

Drug Info

Quick Facts

Related News